Ceftaroline fosamil

Chemical formula: C₂₂H₂₁N₈O₈PS₄  Molecular mass: 684.67 g/mol  PubChem compound: 9852981

Therapeutic indications

Ceftaroline fosamil is indicated for:

Complicated skin and soft tissue infections (cSSTI)

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Soft tissue infection
Infection of skin
and additionally at least one of
Ceftaroline fosamil susceptible species
Ceftaroline fosamil susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Community-acquired pneumonia (CAP)

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Community acquired pneumonia and additionally at least one of
Ceftaroline fosamil susceptible species
Ceftaroline fosamil susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated skin and soft tissue infections (cSSTI)

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Soft tissue infection
Infection of skin
and additionally at least one of
Ceftaroline fosamil susceptible species
Ceftaroline fosamil susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Community-acquired pneumonia (CAP)

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Community acquired pneumonia and additionally at least one of
Ceftaroline fosamil susceptible species
Ceftaroline fosamil susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: ZINFORO Powder for concentrate for solution
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈